STOCK TITAN

BRIGHT MINDS BIOSCIENCES (DRUG) SEC Filings, Aug 2025-Jan 2026

DRUG NASDAQ

Bright Minds Biosciences files as a foreign issuer, and its SEC reports document clinical-stage biotechnology operations, capital formation and public-company governance. Form 6-K reports include interim condensed consolidated financial statements, management's discussion and analysis, executive certifications, material-event releases and exhibits incorporated by reference into Form F-3 registration statements.

The filings cover capital-structure disclosures for common shares, shelf registrations, public offerings and equity distribution arrangements, as well as clinical and regulatory updates for the company's 5-HT receptor agonist pipeline, including BMB-101. They also record operating and financial results, material agreements and shareholder voting matters tied to development-stage CNS drug programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
current report
-
Rhea-AI Summary

Bright Minds Biosciences reported positive topline Phase 2 results from its BREAKTHROUGH trial of BMB-101 in adults with drug‑resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE). The open-label study enrolled 24 patients and met its primary efficacy endpoints in both cohorts, showing robust seizure reductions with a favorable safety profile.

In the Absence cohort (n=11 efficacy‑evaluable), BMB‑101 achieved a 73.1% median reduction in absence seizures lasting at least 3 seconds and a 74.4% median reduction in total seizure time, with p = 0.012. In the DEE cohort (n=6), there was a 63.3% median reduction in major motor seizures, including Lennox‑Gastaut, Dravet, and Rett patients.

BMB‑101 was generally well tolerated, with most adverse events mild or moderate and no treatment‑related serious events. Patients with Absence Seizures also showed a 90% increase in REM sleep without increasing total sleep time. Based on these findings, Bright Minds has begun preparations for global registrational trials in Absence Seizures and DEE and plans to start a Prader‑Willi syndrome study in Q1 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.98%
Tags
current report
-
Rhea-AI Summary

Bright Minds Biosciences Inc. filed a Form 6-K as a foreign private issuer for November 2025. The filing furnishes a news release dated November 17, 2025 as Exhibit 99.1. That news release is incorporated by reference into the company’s two existing Form F-3 shelf registration statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
current report
Rhea-AI Summary

Bright Minds Biosciences Inc. filed an amended Form 6-K to update a prior submission for November 2025. The amendment mainly clarifies that Exhibit 99.1, a news release dated November 6, 2025, is incorporated by reference into two existing Form F-3 shelf registration statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
current report
Rhea-AI Summary

Janus Henderson Group plc and its affiliated Janus Henderson Biotech Innovation Master Fund Ltd report substantial beneficial holdings in Bright Minds Biosciences Inc. The parent reporting person discloses ownership of 1,145,660 shares representing 16.3% of the outstanding common stock, while the fund reports 984,485 shares or 14.0%. Both reporting persons indicate shared voting and dispositive power for their respective holdings and 0 shares of sole voting or dispositive power.

The filing identifies the reporting entities as institutional investors (designations include IA, HC for the parent and IV for the fund), notes that certain subsidiaries act as registered investment advisers, and includes a power-of-attorney authorizing compliance filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
other
-
Rhea-AI Summary

Bright Minds Biosciences' Schedule 13G/A shows Sio Capital Management, LLC beneficially owns 512,338 common shares, representing 7.27% of the outstanding class based on 7,043,989 shares disclosed by the issuer. Sio reports shared voting and shared dispositive power and no sole voting or dispositive power. Sio is a Delaware registered investment adviser to affiliated funds that directly hold the reported shares. A footnote states Sio GP, LLC and Michael Castor may be deemed to have influence, though that beneficial ownership is expressly disclaimed. The filer certifies the holdings are held in the ordinary course of business and not to change control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
other
-
Rhea-AI Summary

Bright Minds Biosciences Inc. filed a Form 6-K attaching its Condensed Interim Consolidated Financial Statements for the six months ended March 31, 2025 and 2024 and its Management's Discussion and Analysis for the second quarter ended March 31, 2025. The filing lists Exhibits 99.1–99.4, including CEO and CFO certifications, and states these interim documents are incorporated by reference into the company’s Form F-3 registration statement (File No. 333-284694). The report is signed by CFO Ryan Cheung and dated August 8, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
current report

FAQ

How many BRIGHT MINDS BIOSCIENCES (DRUG) SEC filings are available on StockTitan?

StockTitan tracks 39 SEC filings for BRIGHT MINDS BIOSCIENCES (DRUG). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for BRIGHT MINDS BIOSCIENCES (DRUG)?

The most recent SEC filing for BRIGHT MINDS BIOSCIENCES (DRUG) was filed on November 16, 2026.